Skip to main content
. 2022 Dec 5;40(12):1722–1760. doi: 10.1038/s41587-022-01582-x

Fig. 2. Monoclonal antibody statistics.

Fig. 2

a, mAbs approved for the first time within the indicated periods, expressed as a percentage of total biopharmaceuticals approved for the first time within the same time period. b, Global annual mAb sales value, expressed as a percentage of total protein-based biopharmaceutical global sales for the indicated years. Financial data from LaMerie Business Intelligence.